The Sequence Specific Homeopathic DNA Remedy System Responds to Discovery of New Form of Asthma

It has long been recognized that asthma is caused by an inflammatory response to allergens in the airways. This form of asthma can be treated by suppression of the inflammatory response by promotion of the anti-inflammatory cytokine, IL-10. Many asthma sufferers, however, do not respond to anti-inflammatory therapy. A new non-inflammatory form of asthma has now been discovered. Scientists have shown that it is due to a deficiency of sphingolipid and disturbed magnesium homeostasis in the cells that line the airways. Sphingolipid deficiency and sub-optimum magnesium homeostasis is a result of a reduction in the activity of the SPT [Suppressor of Ty] gene.

Sequence specific homeopathic DNA remedies have been developed to target the genes IL-10 and SPT to help resolve each of these two different types of asthma respectively.

Introduction

Scientific investigations initiated by Prof Khuda-Bukhsh and carried out over many years[1] have now confirmed that homeopathic remedies interact with the genetic blueprint and increase the expression of many genes. Because the human genome contains genes that promote health as well as genes that cause disease when their expression is increased, it became important to be able to control the specificity of homeopathic remedy / genetic blueprint interactions.

Almost fifty years ago, it was discovered that, in a clinical setting, gene specific targeting could be brought about by the use of homeopathic DNA molecules with defined nucleotide sequences. [for review, see Ref. 2] Based on this advanced homeopathic DNA gene targeting system, a series of sequence specific homeopathic DNA (SSHD) remedies has been developed.

SSHD remedies take into account new properties of DNA that have been realized in recent years.[Review 2] They also take into account important health related scientific discoveries, such as those that have identified diseases that are caused by sub-optimal expression of health promoting genes. In a homeopathic context, studies have also shown that similar disease symptoms can be caused by quite different genetically controlled pathways, as exemplified below.

The significance of the ability to target genes that are involved in quite different forms of the same disease, using the SSHD system, is illustrated by reference to recent discoveries that highlight two completely different forms of asthma.

Allergic Asthma

It has long been thought that asthma is caused exclusively by an allergic reaction in the airways that is driven by airborne particles such as pollen. The allergic reaction results in an inflammatory process that restricts the airways causing breathing difficulties. The asthma causing allergic reaction is due to development of an unusual type of immune response.

Normally, the immune system makes soluble antibodies called IgG, A or M. Sometimes, some people make another type of antibody called IgE. Unlike IgG, A or M antibodies, which circulate in the blood and other body fluids, IgE binds to the surface of mast cells. Mast cells are located within the surface of the airways, as well as other tissues.

An allergic reaction is caused by the binding of a foreign substance, or allergen, such as pollen to mast cell bound IgE in the airways. The binding of allergens to IgE bound to mast cells causes them to disrupt, leading to the release of acute inflammatory mediators such as histamine. It is this inflammatory process that causes the walls of the airways to contract.

The switch from production of beneficial or normal antibody types to IgE production is regulated by the cytokine IL-10. The Homeovitality Allergicare SSHD remedy has been developed to support the activity of the gene that encodes IL-10 so that the likelihood of IgE antibody formation, and hence development of an allergic reaction is reduced. It has also been recently discovered that IL-10 can even suppress the formation of mast cells.[3] In fact, the positive effects of anti-asthma drugs such as triamcinolone and montelukast are considered to be due to their ability to increase IL-10 production.[4] IL-10 is also an important anti-inflammatory cytokine.

Anti-inflammatory and immunosuppressive agents such as corticosteroids are routinely used to help resolve the symptoms of asthma; however, such agents provide relief for only about half of patients suffering from this disease.

Non-inflammatory Asthma

Scientists at Columbia University, New York[5] have recently identified a completely new type of asthma. Their discovery provides an explanation for the fact that many sufferers do not respond to immunosuppressive agents such as corticosteroids.

The newly recognized form of non-inflammatory asthma is due to a deficiency of a cell membrane component called sphingolipid (SL) in cells that line the airways. Activity of the gene SPT that encodes the enzyme serine palmitoyl-CoA transferase has been shown by Dr Worgall and colleagues[5] to play a critical role in the production of SL to suppress the onset of non-allergic asthma. They showed that SL deficiency, due to decreased SPT activity, leads to non-inflammatory hyper-reactivity and contraction of the airways. Furthermore, they showed that decreased SL synthesis is also associated with altered magnesium homeostasis. Magnesium, the second most abundant cellular cation after potassium, is essential for regulation of numerous cellular functions and stabilization of enzymes which are involved in maintenance of effective airway physiology.

To respond to this newly recognized non-inflammatory form of asthma, the Homeovitality SSHD remedy STeP1 has been developed to target the SPT gene.

As indicated above, administration of immunosuppressive and anti-inflammatory agents in this latter form of asthma have no beneficial effect; rather, they suppress immunity, increasing the patient’s susceptibility to lung infection.

Comments:

Post Your Comments:

Dr Peter Kay PhD specialized in blood group serology and haematology in the UK. In 1974, he moved to Australia and became involved in tissue transplantation serology and autoimmunity. He later became a member of the Dept of Pathology at the University of Western Australia, specialising in Immunopathology. In the late 1980s he was awarded his PhD, subject matter, Immunogenetics. In 1989, he founded the first Molecular Pathology laboratory in Western Australia in the Faculty of Dentistry and Medicine at the University of Western Australia, and remained as Head until he retired from Academia in 2001. He has published over 80 peer reviewed articles in prestigious international scientific journals.

Since 2001 he has discovered how hybrid vigour works. His discoveries, which will revolutionize agricultural practices worldwide, are embodied in two filed Patents, WO 2005/075668 and WO 2007/012138. Peter Kay may be contacted on Tel: 01772 691443; peterhkay@gmail.com

Saqib Rashid BSc MSc DHM (BIH) Saqib is a fully qualified and experienced Homeopath. He has attained a BSc degree and later an MSc degree in physics. He achieved his postgraduate diploma in Homeopathic medicine (DHM), from the British Institute of Homeopathy, Egham, Surrey.

His passion is to treat his patients holistically under the strict guidelines of homeopathic practice. His special interest in homeopathy is to treat children who are suffering with problem like Autism (ASD), Asperger's syndrome ADHD, dyslexia, issues of retarded growth and people with medically unexplained symptoms or illnesses, and those who did not achieve great results from other forms of treatment. Saqib currently runs a successful homeopathic practice in Wandsworth, South West of London and may be contacted via Mob: 07897 438436; saqib@homeovitality.com